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Introduction:Defects of prokineticin pathway affect the neuroendocrine control of reproduction,
but their role in the pathogenesis of central hypogonadism remains undefined, and the functional
impact of the missense PROKR2 variants has been incompletely characterized.
Material andMethods: In a series of 246 idiopathic central hypogonadismpatients,we found three
novel (p.V158I, p.V334M, and p.N15TfsX30) and six already known (p.L173R, p.T260M, p.R268C,
p.V274D, p.V331M, and p.H20MfsX23) germline variants in the PROKR2 gene. We evaluated the
effectsof sevenmissensealterationson twodifferentprokineticin receptor2 (PROKR2)-dependent
pathways: inositol phosphate-Ca2 (Gq coupling) and cAMP (Gs coupling).
Results: PROKR2 variants were found in 16 patients (6.5%). Expression levels of variants p.V158I
and p.V331M were moderately reduced, whereas they were markedly impaired in the remaining
cases, except p.V334M,whichwas significantly overexpressed. The variants p.T260M, p.R268C, and
p.V331M showed no remarkable changes in cAMP response (EC50) whereas the IP signaling ap-
peared more profoundly affected. In contrast, cAMP accumulation cannot be stimulated through
the p.L173R and p.V274D, but IP EC50 was similar to wt inp.L173R and increased by 10-fold in
p.V274D. The variant p.V334M led to a 3-fold increase of EC50 for both cAMP and IP.
Conclusion: Our study shows that single PROKR2 missense allelic variants can either affect both
signaling pathways differently or selectively. Thus, the integrity of both PROKR2-dependent cAMP
and IP signals should be evaluated for a complete functional testing of novel identified allelic
variants. (J Clin Endocrinol Metab 99: E458–E463, 2014)
Research on the prokineticin system has revealed itsinvolvement in several physiological mechanisms
and pathological conditions. The knockout models for
both ligand [prokineticin 2 (Prok2)] and the G protein-
coupled receptor, Prokr2, revealed a role in olfactory
bulb morphogenesis and sexual maturation, indicating
PROK2 and PROKR2 as strong candidate genes for
human GnRH deficiency (1, 2). The involvement of
PROKR2 in the pathogenesis of hypogonadotropic hy-
pogonadism (HH) was first described in 2006 (3) and
subsequently reported in several other patients series
(4). Idiopathic HH is a rare disease with a complex
pathogenesis but a strong genetic component. It is
characterized by delayed or absent puberty secondary
to gonadotropin deficiency and associated or not with
olfactory defects in the Kallmann’s syndrome (KS)
or in the normosmic isolated HH (nIHH), respectively
(4).
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.
Copyright © 2014 by the Endocrine Society
Received June 5, 2013. Accepted November 13, 2013.
First Published Online November 25, 2013
* Author affiliations are shown at the bottom of the next page.
Abbreviations: CHg, central hypogonadism; CPHD, combined pituitary hormone deficit;
FACS, fluorescence-activated cell sorter; HEK, human embryonic kidney; HH, hypogo-
nadotropic hypogonadism; ICL, intracellular loop; IP, inositol phosphate; KS, Kallmann’s
syndrome; LOF, loss of function; nIHH, normosmic isolated hypogonadotropic hypogo-
nadism; Prok2, prokineticin 2; Prokr2, prokineticin receptor 2; TMH, transmembrane helix;
wt, wild type.
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Very recently PROKR2 variants have been also de-
scribed in patients with idiopathic combined pituitary
hormone deficits (CPHDs), including gonadotropin defi-
ciency (5–7). Importantly, all previous in vitro studies on
the identified allelic variants were showing variable im-
pairments of PROKR2 function (5, 6, 8–11) either involv-
ing the expression level of the variant receptors or their
ability to stimulate the Gq-dependent pathway. No direct
data are so far available about the effect of these variants
on the Gs-dependent cAMP signaling, despite evidence of
its activation by nanomolar concentrations of PROK2
(12). Because a variable involvement of diverse transduc-
tionpathwaysbya single genetic varianthasbeen reported
for other G protein-coupled receptors (13), we decided to
characterize the PROKR2 genetic variations identified in
a large Italian series of idiopathic central hypogonadism
(CHg) patients by evaluating both either their direct ex-
pression on living-cell membrane and their ability to ac-
tivate the two signal transduction pathways linked to the
PROKR2.
Materials and Methods
Patients
A large cohort of Italian patientswithCHgwas collected (n
197 males and 49 females) thanks to the Italian network for
idiopathic CHg supported by the Italian Societies of Endocri-
nology, and of Pediatric Endocrinology and Diabetes. The CHg
cohort includes KS (41%), nIHH (54%), or idiopathic CPHD
patients (5%). The institutional Ethics Committee approved the
study and all patients gave their informed consent for the genetic
investigations. The patients’ entire open reading frame of the
human PROKR2 gene was amplified by PCR (primers available
upon request) and sequenced according to standard protocols.
Expression and bioassays of PROKR2 variants
PROKR2 wild-type (wt) plasmid (Missouri S&T cDNA
Resource Center) was used as a template to engineer the
tested mutants (see Supplemental Material, published on The
Endocrine Society’s Journals Online web site at http://jcem.
endojournals.org). PROKR2 variant expression was checked by
fluorescence-activated cell sorter (FACS), immunocytochemis-
try and Western blot, whereas cAMP and inositol phosphate
(IP)-1 bioassays were performed in transient transfection on hu-
man embryonic kidney (HEK)-293 or COS7 cells following pre-
viously described protocols (14) with specific modifications (see
Supplemental Material).
Statistics
The data presented were from representative experiments.
Differences between means were compared using an unpaired
Student’s t test and ANOVA with Dunnett post hoc test.
Results
Genetic analysis
The analysis of the PROKR2 gene led to the identifi-
cation of 16 patients carrying exonic variations of 246
CHg patients (6.5%). All the variants were present in the
heterozygous state, except in one case (Table 1). Nine dif-
ferent variants were identified: seven missense substitu-
tions (p.V158I, p.L173R, p.T260M, p.R268C, p.V274D,
p.V331M, and p.V334M) and two frame shift deletions
generating premature stop codons (p.N15TfsX30 and
p.H20MfsX23). Six variants had been previously identi-
fied (p.L173R; p.T260M,p.R268C, p.V274D, p.V331M,
and p.H20MfsX23) (15, 16). All these variations affect
well-conserved residues, and none of these variations
was observed in 300 control alleles from the adult gen-
eral population. The analysis of other candidate genes
(KAL-1,FGFR1,FGF8,GnRHR,GnRH1,TAC3,TAC3R,
KISS1R, CHD7, PROK2, and SEMA3A) allowed the
identification of a second heterozygous variant in 4 of 16
patients (Table 1).
Clinical characteristics
The main clinical features of the 16 patients with
PROKR2 gene variations are reported in Table 1. No sta-
tistically significant correlations were found between the
presence/absenceof thegenetic variationsandclinical phe-
notypes and/or parameters such as LH/FSH and sex ste-
roids levels (data not shown). All patients, but one, expe-
rienced a pubertal delay and the reversal of CHg was
documented in three. Variable CPHDs were detected in
three cases. Familial history revealed the recurrence of
anosmia in an aunt of KS-1 carrying the wt-PROKR2
allele and a pubertal delay in the heterozygous mother of
KS-6. The PROKR2 gene investigations in the families
failed to show cosegregation with phenotype, as previ-
ously reported (5, 7, 11, 17). In KS-2, nIHH-1, and
nIHH-7, the phenotype appeared in the family in associ-
ation with the biallelic defect.
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Functional and molecular studies
The two frame shift variants, p.N15TfsX30 and
p.H20MfsX23, led to the generation of a protein lacking
all the transmembraneand intracellular receptordomains,
thus justifying the classification asmutationswith a severe
loss of function (LOF).
All missense mutants showed an impaired targeting on
the cell surface, exception made for p.V334M, which is
more efficiently expressed on the HEK293 membrane
compared with the wt (Figure 1, A and E, and Supple-
mental Figure 1). Both FACS analysis after cell permea-
bilization andWestern blotting showed a similar levels of
receptorprotein expression (Supplemental Figure2,Aand
B), consistent with reproducible transfection efficiencies
and the stability of translated proteins.
Two different bioassays were performed. Basal IP1 lev-
elswere similar for all PROKR2variants.Differently, con-
centration-effect curves showed a variable right-shift
modificationof theEC50 in four tested variants (p.R268C,
p.V274D, p.V331M, and p.V334M), whereas p.T260M
had a borderline shift of the response curve (Figure 1, B
and E) and a normal response was observed for the re-
maining two variants (p.V158I and p.L173R). The testing
of theGs-cAMPpathway did not reveal difference at base-
line in any case but showed normal or statistically signif-
icant increase of theEC50 for two (p.V158I andp.V331M)
or three variants (p.T260M, p.R268C, and .V334M), re-
spectively. The remaining two variants, p.L173R and
p.V274D displayed the complete lack of intracellular
cAMP response, demonstrating a severe derangement of
the Gs coupling (Figure 1, C and E).
Because the variants behave differently in the three bi-
ological parameters examined, we considered the gener-
ationofa functional score integratingall these results.This
score generates the ranking of PROKR2 variants (Supple-
mental Figure 3), with p.V274D, p.T260M, p.R268C,
and p.L173R showing a complete or severe LOF; the re-
maining missense mutants (p.V331M, p.V334M, and
p.V158I) conserve 50%–70% of wild-type activities.
Discussion
We report the frequency of PROKR2 gene variants in
about 6.5% of CHg patients belonging to the largest Ital-
ian cohort so far investigated. This frequency appears
comparable with that of the French population (3) but
slightly higher in comparison with the US population (9).
To understand their pathogenic role, we extensively char-
acterized all the missense variants by testing the dual ac-
tivation of Gq- andGs-dependent pathways, andwe iden-
tified variations with a predominant impact on one or the
other downstream signal.
At variancewithprevious studies (8, 9),weusedadirect
method to test the expression of the mutated constructs at
the cell surface. A hampered membrane targeting was de-
tected in all cases, except the variant p.V334M, which
exhibited an enhanced level of expression on the cellmem-
brane. We therefore verified either the capacity for Gq or
Table 1. Clinical and Genetic Parameters of the CHg Patients With PROKR2 Allelic Variants
Patients
Sex and
Age at
Diagnosis, y
cDNA
Mutation
Protein
Mutation Zygosity
Associated
Gene
Variantsa
MRI Olfactory
Structure
Sense of
Smell Familial Manifestations Phenotypic Details
KS-1 M, 14 c.472 GA p.V158I Hetero None Hypoplastic H Anosmia in
aunt with
wt PROKR2
—
KS-2 M, 15 c.518 TG p.L173R Hetero FGFR1: c.IVS17-6 CT Hypoplastic A — —
KS-3 M, 16 c.518 TG p.L173R Hetero None Hypoplastic A — —
KS-4 M, 20 c.779 CT p.T260M Hetero None Absent A — —
KS-5 M, 18 c.802 CT p.R268C Hetero None Absent A — —
KS-6 M, 19 c.820 TA p.V274D Homo None Absent A Pubertal delay
in hetero
mother
CHg reversal
nIHH-1 M, 14 c.518 TG p.L173R Hetero FGFR1: p.Q89R Normal N — Partial empty sella
nIHH-2 M, 20 c.518 TG p.L173R Hetero None Normal N — —
nIHH-3 M, 18 c.802 CT p.R268C Hetero None Normal N — —
nIHH-4 M, 12 c.1000 GA p.V334M Hetero PROK2: p.C383FfsX1 Normal N — —
nIHH-5 F, 16 c.1000 GA p.V334M Hetero None Normal N — —
nIHH-6 M, 21 c.56delC p.H20MfsX23 Hetero None Normal N — CHg reversal
nIHH-7 M, 18 c.43insACTTT p.N15TfsX30 Hetero GNRHR: p.Q106R nd N — CHg reversal
CPHD-1 M, 22 c.779 CT p.T260M Hetero None Normal N — Adult GHD; OB
CPHD-2 M, 37 c.991 GA p.V331M Hetero None Normal N — CHa; T2DM; OB
CPHD-3 M, 58 c.56delC p. H20MfsX23 Hetero None Normal N — Adult-onset CHt;
T2DM; OB
Abbreviations: A, anosmia; CHa, central hypoadrenalism; CHt, central hypothyroidism; F, female; GHD, GH deficit; H, hyposmia; Hetero, heterozygosity;
M, male; MRI, magnetic resonance imaging; N, normal; nd, not determined; OB, obesity; T2DM, type 2 diabetes mellitus; —, none of interest.
a Associated genetic variants found in heterozygosity.
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Figure 1. A, Flow citofluorometry analysis, FACS, of intact HEK293 cells transiently transfected with wt PROKR2 or the identified variants. Results
are expressed as fold of wt. The Prism computer program (GraphPad Software, Inc) was used for statistical analysis: Student’s t test in comparison
with the wt: ***, P  .0001, **, P  .001; ANOVA with Dunnett post hoc test: °°, P  .01, °, P  .05. The figure illustrates the integrated results
(mean  SE) of three independent experiments. B and C, Concentration-effect curves for the PROKR2 variants under stimulation of increasing
concentrations of human recombinant PROK2. HEK293 cells transiently transfected with the various constructs were stimulated, and intracellular
IP1 (B) or cAMP (C) values were determined. The results are expressed as fold of wt. The Prism computer program (GraphPad Software) was used
for curve fitting and for EC50 determination. The figure shows the integrated results (mean  SE) of six independent experiments. D, Homology
models of the inactive (boxed window) and active PROKR2 conformations. The receptors (helices and loops) are visualized by cartoon
representation (white) and the three subunits of Gs are shown with different colors. On these structural PROKR2 models, wt positions (sticks) of
investigated single side-chain substitutions are highlighted. The colors encode specific functional effects of these variants: green, Gs and Gq
signaling were both decreased; cyan, slightly effected expression level; magenta, selectively impaired Gq signaling. During receptor activation-
transition between inactive and active signaling state, the transmembrane helices (TMHs) 5, 6, and 7 are predicted to undergo significant structural
rearrangements (indicated by red arrows) with participation of specific amino acids. Helix 5 is extended in the active conformation compared to
the inactive state and TMH6 is shorter at the intracellular site. The mutations described here are located at different spatial receptor regions. I,
Variant p.V158I (slightly decreased cell surface expression level) is located at the junction between the transmembrane helix 3 (TMH3) and
intracellular loop 2 (ICL2) and sticks into the cytoplasm without interior intramolecular contacts. II, The side chain of substitution p.L173R
(positively charged) in TMH4 points toward TMH3 (to A148). This mutant leads to decreased levels of cell surface expression, decreased maximal
IP, and impaired cAMP signaling. This supports that the arginine substitution (large, branched, positively charged) is not tolerated in a hydrophobic
cage at TMH3 instead of a large and branched hydrophobic wt leucine side chain. III) The selectively inactive (Gq) p.T260M variant is located in the
ICL3 but is part of the junction between TMH5 and ICL3 in the active-state
doi: 10.1210/jc.2013-2431 jcem.endojournals.org E461
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 09 June 2016. at 09:20 For personal use only. No other uses without permission. . All rights reserved.
the Gs signal transduction pathway of wt and mutants
(Figure 1, B, C, and E). Although the ability to stimulate
the Gq pathway was affected in most of the cases, this
functionwaswell conserved for the p.V158I. Themutants
p.R268C and p.V274D are both strongly lacking the abil-
ity to activate the Gq protein, whereas no activation of
cAMP accumulation was detected in cells expressing the
p.L173R and p.V274D constructs. Importantly, the se-
vere LOF of the p.V274D mutant on both of the trans-
duction pathways cannot be explained ononly the basis of
a poor membrane targeting because similar low surface
expression levels were seen for both p.V274D and
p.L173Rmutants, but p.L173Rwas still able to normally
activate the Gq-dependent pathway.
The functional evaluation of the p.L173R mutant rep-
resents another clear demonstration of the importance to
evaluate the dual PROKR2 signaling. Although the mem-
brane expression and the mechanisms leading to the Gq
activation appear only partially compromised, the com-
plete loss of the ability to stimulate theGs-dependentpath-
way amplify the pathogenic impact of this particular vari-
ant. In addition, structural receptor models (Figure 1D)
suggest two main messages on the molecular level for the
tested substitutions (see the figure legend for details): 1)
mutations like p.V274D [transmembrane helix (TMH)-6]
or p.V334M and p.L173R modify the intrinsic signaling
capacity of PROKR2 by modifying specific biophysical
properties in structural parts participating significantly in
receptor activation (eg, TMH6 and TMH7 interfaces);
and 2) especially amino acid T260, R268 selectively in-
fluence Gq coupling and they are located at the intracel-
lular transitions between intracellular loop (ICL)-3 and
TMH5/TMH6, which is a potential direct G-protein con-
tact region.
In light of our findings, the pathogenic role of muta-
tions found in CHg patients can bemisclassified if a single
pathway is analyzed because the dual-signal ability of
PROKR2 appears to be differentially affected by the vari-
ations detected in this large CHg cohort. The extensive
functional analysis here reported (FACS, IP1, and cAMP
assays) were therefore integrated in a formula that gener-
ates a score giving a comprehensive characterization of
each variant (see Supplemental Figure 3). Then the
p.V158I receptor represents a rather benign variation; in-
stead p.L173R and p.V331Mgenerate a severe damage of
only one intracellular pathway (either Gq or Gs), whereas
both of the transduction pathways were simultaneously
affected to variable degrees in the remaining cases,
p.V274D being the variant provided with an almost com-
plete LOF.
Because the inactive p.V274D variant was found in the
homozygous state in KS-6 case with spontaneous reversal
of GnRH neuron function (18), our data indicate that a
severe PROKR2 LOF can cause only a partial impairment
ofGnRHneuron function, whichmay be overcome by the
plasticity of the neuronal network. In addition, the case
CPHD-3 is carrying a mutation predicted to generate a
truncated protein lacking all the transmembrane domains
but came to the physician’s attention because of typical
hypogonadal manifestations at 58 years. He reported to
have spontaneously fathered two daughters and transmit-
ted the same heterozygous PROKR2 mutation to one of
them, who spontaneously conceived and very recently de-
livered one baby. These data are consistent with a report
describing the complex inheritance with highly variable
penetrance among carriers of the ancient founder muta-
tion p.L173R (17). The whole of these data indicates that
PROKR2 variants may indeed be found as rare polymor-
phisms in the general population and that the presence of
PROKR2 variations can partially weaken (likely to vari-
able extents, depending on the severity of the functional
alteration) theGnRHfunction andpredispose toCHgand
reproductive defects, but other genetic or acquired defects
may be required to obtain the full-blown isolatedHHphe-
notype. Consistently, the digenic defects were found here
only in the KS or nIHH patients.
In conclusion, routine assessment of the impact of
PROKR2 variants on both the cAMP and IP pathways is
warranted to avoid absolving mutations that selectively
compromise one signaling branch while leaving the other
intact and thereby to avoid erroneously predicting a re-
duced risk of disease in the variant-carrying progeny of
such patients.
Figure 1. (Continued). conformation with an extended helix 5 that is
of importance for receptor/G protein contact and activation. IV) The
mutation p.R268C is located at the transition between TMH6-ICL3 and
therefore might have a more direct impact on the receptor/Gq contact.
V) According to the functional characterization of the p.V274D
substitution, V274 is a key player for signal transduction. The drastic
change from hydrophobic to hydrophilic side-chain properties likely
impedes the helix-movement between TMH5 and TMH6 that is a
general prerequisite for G protein activation. VI) Mutants p.V331M and
p.V334M were characterized to inhibit Gq signaling, and they are
located at the TMH7, close to the intracellular site. In the inactive state,
side chains of V331 and V334 point toward the membrane, whereby
V334 is predicted to rotate slightly toward TMH1 during receptor
activation (Gs). It cannot be excluded that they might participate in
intermolecular contacts, as previously suggested (19). Further
experiments based on the cotransfection of wt and variant PROKR2
will be worthy to confirm such possibility. Structure images were
produced using PyMOL software (The PyMOL molecular graphics
system, version 1.3; Schrödinger LLC). E, Summarized data indicating
the functional results of the PROKR2 allelic variants. Data are expressed
as mean  SE of three FACS or six independent signaling experiments,
respectively. ***, P  .0001 vs wt; **, P  .001 vs wt; *, P  .01 vs
wt using Student’s t test; °, P  .05 vs wt, °°, P  .01 vs wt using
ANOVA with Dunnett post hoc test.
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